Medication–induced hyperprolactinemia is more common than you might think and it can produce detrimental long-term health sequelae. In this podcast, we will review the work-up and management of this common side effect.
Psychogenic polydipsia (PP), also known as primary polydipsia and potomania, was first described in the 1930s. It is surprisingly common with a prevalence rate between 3 to 25% in institutionalized patients. In this podcast, we will discuss how to accurately diagnose and manage psychogenic polydipsia in patients.
Stephan Heckers, MD
William P. and Henry B. Test Professor Chair, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center. Psychiatrist-in-Chief, Vanderbilt Psychiatric Hospital. Nashville, TN.
Dr. Heckers has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Patients experiencing catatonia often improve quickly with benzodiazepines, but how can we help patients who fail to respond? Dr. Heckers summarizes the management of catatonia, including refractory cases, and tells us of other illnesses to consider in our differential diagnoses.
Stephen J. Seiner, MD
Director of neurotherapeutics, McLean Hospital. Belmont, MA.
Dr. Seiner has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Dr. Seiner runs one of the busiest ECT programs in the country and speaks to us about recent innovations in the procedure. He also tells us which patients are the best candidates and shares tips for how to prolong ECT’s benefits.
Susie Morris, MD.
Assistant professor of psychiatry and forensic psychiatrist, UCLA. Los Angeles, CA.
Dr. Morris has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Compulsive water drinking, or psychogenic polydipsia, is surprisingly common on inpatient psychiatric units. We learn how to diagnose and manage this potentially life-threatening condition.
KarXT (Cobenfy) is the first antipsychotic that doesn’t block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three...